New MHRA Guidance acknowledges the need to monitor for VND
Redsense Medical announces today that the UK Medicines & Healthcare Products Regulatory Agency (MHRA) has issued a new dialysis guidance, in which venous needle dislodgement (VND) is explicitly acknowledged as an important issue that should be addressed to ensure the safety of patients. Currently, Redsense offers the only standalone blood loss monitor registered with the MHRA for use on the UK market.The MHRA is the UK executive agency responsible for ensuring the safety and regulatory compliance of medicines and medical devices in the UK market. On March 8, 2022, the MHRA published an